However, a larger study of PD-L1 expression as a biomarker of response in solid tumors including melanoma reported that the correlation is not as solid as reported, because some patients with PD-L1 negative tumors had clinical responses to nivolumab (http://meetinglibrary.asco.org/content/113904-132). This evidence concerns the gene CD274 and melanoma.